Duke to Participate in Early Clinical Trials for Emerging Neurological Therapies

< p > Contact: Samiha Khanna < br / > < span style= " line-height: 1.2em; " > Phone: [phone] < br / > < /span > < span style= " line-height: 1.2em; " > Email: < /span > < a href= " mailto:[e-mail] " style= " line-height: 1.2em; " > [e-mail] < br / > < /a > < span style= " line-height: 1.2em; " > https://www.dukehealth.org < /span > < /p > < p > < span style= " line-height: 1.2em; " > FOR IMMEDIATE RELEASE on Thursday, July 21, 2016 < /span > < /p > < p > < span style= " line-height: 1.2em; " > DURHAM, N.C. -- Duke University could receive up to $19 million to lead early-stage clinical trials for new drugs to treat neurological conditions such as Alzheimer ’s disease and neuropathy. < /span > < /p > < p > < span style= " line-height: 1.2em; " > The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, awarded the 10-year contract to Duke to design, manage, and conduct Phase I clinical trials. The trials will be conducted at the Duke Clinical Research Unit (DCRU), the early-phase clinical trial unit of the Duke Clinical Research Institute. The DCRU ’s state-of-the-art 40-bed study and observation facility is one of a small number of academic early phase research units in the country. < /span > < /p > < p > < span style= " line-height: 1.2em; " > Support for the contract will be provided as part of the NIH Blueprint for Neuroscience Research Neurotherapeutics Network. The goal of the network is t...

Source: DukeHealth.org: Duke Health Features - July 21, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news